Last reviewed · How we verify
SCTC21C
SCTC21C is a chimeric antigen receptor T-cell (CAR-T) therapy engineered to target and eliminate cancer cells expressing specific tumor-associated antigens.
SCTC21C is a chimeric antigen receptor T-cell (CAR-T) therapy engineered to target and eliminate cancer cells expressing specific tumor-associated antigens. Used for Hematologic malignancies (specific indication under investigation in phase 3).
At a glance
| Generic name | SCTC21C |
|---|---|
| Sponsor | Sinocelltech Ltd. |
| Drug class | CAR-T cell therapy |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
CAR-T cell therapies involve genetically modifying a patient's own T cells to express chimeric antigen receptors that recognize tumor-specific antigens, enabling enhanced recognition and killing of malignant cells. SCTC21C is designed to redirect T-cell specificity toward cancer cells while minimizing off-target effects. This approach leverages the patient's immune system for durable anti-tumor activity.
Approved indications
- Hematologic malignancies (specific indication under investigation in phase 3)
Common side effects
- Cytokine release syndrome
- Neurotoxicity
- Cytopenias
- Infections
Key clinical trials
- A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis (NDSLCA) (PHASE3)
- A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant (PHASE3)
- A Clinical Study of SCTC21C in Participants With Plasma Cell-driven Autoimmune Diseases (PHASE1, PHASE2)
- A Clinical Study of SCTC21C in Participants With CD38+ Hematologic Malignancies (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SCTC21C CI brief — competitive landscape report
- SCTC21C updates RSS · CI watch RSS
- Sinocelltech Ltd. portfolio CI